Filing Details
GT Biopharma, Inc. (NASDAQ:GTBP) filed a Form 8-K with the Securities and Exchange Commission on November 12, 2026, disclosing a material event.
GT Biopharma, Inc. (NASDAQ:GTBP) filed a Form 8-K with the Securities and Exchange Commission on November 12, 2026, disclosing a material event.

At publication ·
GT Biopharma, Inc. (NASDAQ:GTBP) · 8k filed
At a glance
GT Biopharma, Inc. (NASDAQ:GTBP) filed a Form 8-K with the Securities and Exchange Commission on November 12, 2026, disclosing a material event.
GT Biopharma, Inc.'s stock currently trades at $3.95 with a market capitalization of $6.8M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for GT Biopharma, Inc.'s stock.
All SEC filings for GT Biopharma, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View GTBP Stock Page
Browse all filings on our GTBP SEC filings page.
Public companies like GT Biopharma, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
Current market data
NASDAQ · GTBP
$2.96
Down: -$0.22 · -6.92%
Live quote updated
Keep reading
earnings ·
earnings ·
sec_filing ·
sec_filing ·